Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Activity of Talviraline (HBY 097) +/- AZT in HIV
NCT00002357Phase 2Completed
- Sponsor
- Hoechst Marion Roussel
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of talviraline in human immunodeficiency virus infection (HIV) (6 arms), sponsored by Hoechst Marion Roussel. Primary endpoints: Safety and Tolerability at 12 weeks and Antiretroviral Activity (HIV-1 RNA) at 12 weeks. Status: completed.
02
Drugs
talviraline
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002357.